Publications by authors named "Pascal Rufi"

Claim this Profile
evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43.
Paul Lang, Svend S Geertsen, Alex L Lublin, Michelle C Potter, Tatiana Gladysheva, Pascal Rufi

Biochem Biophys Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.
Patricia K Coyle, Bhupendra Khatri, Keith R Edwards, José E Meca-Lallana, Steve Cavalier, Pascal Rufi

Mult Scler Relat Disord· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Sandra Vukusic, David Brassat, Jerome de Seze, Guillermo Izquierdo, Andreas Lysandropoulos, Pascal Rufi

Mult Scler Relat Disord· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Patricia K Coyle, Bhupendra Khatri, Keith R Edwards, José E Meca-Lallana, Steve Cavalier, Pascal Rufi

Mult Scler Relat Disord· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.
Patricia K Coyle, Bhupendra Khatri, Keith R Edwards, José E Meca-Lallana, Steve Cavalier, Pascal Rufi

Mult Scler Relat Disord· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.
Maria Pia Sormani, Philippe Truffinet, Karthinathan Thangavelu, Pascal Rufi, Catherine Simonson

Neurol Neuroimmunol Neuroinflamm· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis